ZYN Peppermint 3 mg is a real, FDA-authorised product — one of 43 nicotine pouch products that may lawfully be sold in the United States, and one of only 20 that may carry FDA’s reduced-risk claim. This is a first look, based on manufacturer specifications and FDA’s own filings. I have not used this product, so there are no scores anywhere on this page and no tasting notes. What I can tell you is unusually well documented: FDA publishes this pouch’s exact dimensions, mass and nicotine load, and has put on the record that it is bioequivalent to a flavour that has been through a published pharmacokinetic study.
What it is, in the regulator’s own numbers
This review starts from a marketing granted order rather than from the can, because for ZYN the US regulator publishes more hard specification than the manufacturer does.
FDA authorised twenty ZYN products on 16 January 2025, under submission tracking numbers PM0000593.PD1 to PM0000612.PD1. Appendix A of that order lists each one field by field. For Peppermint 3 mg, the entries are: product quantity 6g; characterizing flavour Flavored, identified as Peppermint; nicotine source Tobacco; Nicotine Concentration: 3 mg/pouch; Portion Count: 15 pouches; Portion Mass: 0.40 g; Portion Length: 28 mm; Portion Width: 14 mm; Portion Thickness: 4.5 mm.
Two things there are worth pausing on. “Nicotine source: Tobacco” does not make this a tobacco product in the ordinary sense: FDA’s technical review says the products “are not smokeless tobacco products because they do not consist of cut, ground, powdered, or leaf tobacco.” The nicotine is extracted from tobacco; no leaf goes in the pouch — a distinction that decides how several states tax and regulate it.
And the mass. A published pouch weight is rarer than you would expect; across the major brands ZYN is close to alone in printing one, and its FAQ’s “approximately 0.4 grams” agrees exactly with FDA’s 0.40 g. That agreement is the only route from a per-pouch figure to a per-gram one. At 3 mg in 0.40 g, this pouch is 7.5 mg/g — my arithmetic, not anyone’s published number.
Specifications
| Item | Figure | Source |
|---|---|---|
| Nicotine per pouch | 3 mg | FDA marketing granted order, Appendix A |
| Nicotine per gram | 7.5 mg/g | Derived by me from 3 mg ÷ 0.40 g — not published by anyone |
| Pouch mass | 0.40 g | FDA order; corroborated by ZYN’s own FAQ (“approximately 0.4 grams”) |
| Pouch dimensions | 28 × 14 × 4.5 mm | FDA order (not published on any ZYN page) |
| Pouches per can | 15 | FDA order; ZYN FAQ: “Every can of ZYN contains 15 nicotine pouches” |
| Can net weight | 6 g | FDA order |
| Nicotine source | Tobacco-derived | FDA order; FDA review confirms no leaf, cut or ground tobacco |
| pH | Not published | ZYN names its pH adjusters but gives no value; FDA’s review redacts it |
| FDA authorisation | Granted 16 January 2025 (PMTA) | FDA marketing granted order |
| FDA modified-risk order | Granted 30 June 2026, five-year term | FDA modified risk granted order, STN MR0000268.PD3 |
Ingredients, as ZYN groups them by function: nicotine salt (nicotine bitartrate dihydrate), stabilisers (hydroxypropyl cellulose), fillers (microcrystalline cellulose, maltitol, gum arabic), pH adjusters (sodium carbonate and bicarbonate) and sweetener (acesulfame K) — “In addition to nicotine salt, ZYN contains only food-grade ingredients.”
The pH omission is the one I would most like closed. Free-base fraction — the share of nicotine that is uncharged and can cross the mucosa — moves with pH, and across the category it varies enormously: a US CDC survey of 37 brands found a pH range from 6.94 to 10.1, which BfR converted to free-base proportions “of 7.7% to 99.2%”. A thirteen-fold swing in the fraction that can actually get in is a bigger lever than the gap between a 3 mg and a 6 mg pouch, and no manufacturer publishes it.
What a 3 mg pouch actually delivers
Nobody has run a pharmacokinetic study on ZYN Peppermint 3 mg. What exists is a 2020 study by Lunell and colleagues which tested ZYN 3 Smooth — ordinarily a weak bridge, since a different flavour is a different product. But FDA closed the gap itself, in its review of these very applications: nicotine exposure from Smooth 3 mg and from “the mint-flavored new products” including Peppermint 3 mg “are bioequivalent even though these new products have different flavor ingredients”, because “Published data show that flavor ingredients do not significantly affect nicotine release from commercially available nicotine pouches”. It is rare to get a regulator stating on the record that a tested product and an untested one behave alike.
So what does the 3 mg tier do? The Dutch public-health institute RIVM, which has no industry funding, worked it out from the published data: “De vrijgekomen dosis van 1,6 mg nicotine bij gebruik van een nicotinezakje met 3 mg nicotine gedurende één uur (ZYN 3 mg) is daarom vergelijkbaar met het roken van één sigaret per uur” — a released dose of 1.6 mg from a 3 mg pouch held for an hour, comparable to smoking one cigarette per hour. RIVM gives the peak plasma figure as 8 ng/mL, against 12.8 ng/mL for one cigarette in the study it compares against. The German regulator BfR separately records the extraction rates from the same Lunell work; the independent BfR-funded team of Mallock-Ohnesorg and colleagues restates them as “mean extraction rates of 56%, 59%, and 50% for pouches with 3, 6, and 8 mg nicotine, respectively”.
On provenance: the Lunell paper sits behind a paywall I could not open, so those figures come from two regulators’ restatements rather than from the paper itself. It was funded by Swedish Match and has a Swedish Match scientist among its authors — which is why I would rather quote RIVM’s and BfR’s handling of it than its abstract.
Read plainly: a 3 mg pouch held for an hour puts roughly half its nicotine into you and lands near one cigarette’s worth — delivered over twelve times as long, at a markedly lower peak. It is not so much a weak product as a slow one.
Measured against the label — and the gap in the record
The honest answer is that nobody has measured a 3 mg ZYN independently. The most thorough physicochemical study of pouches, published in Scientific Reports in January 2026, found “The nicotine content in Zyn and Loop pouches was found to be 5.4 mg/pouch and 9.1 mg/pouch, slightly below the target of 6 mg/pouch and 9.4 mg/pouch” — but its methods rule it out as evidence about this product: “To be consistent, all products were mint flavored with nicotine levels between 6 and 9.4 mg per pouch based on the can label.” That was a 6 mg ZYN, not a 3 mg one.
That study needs its funding stated every time: it “was funded by Altria Client Services LLC, an affiliate of Helix Innovations LLC, the manufacturer of on! nicotine pouches”, and all eight authors were Altria employees at the time. Altria makes ZYN’s only authorised competitor. That does not make the measurement wrong — it means one 5.4 mg figure from a competitor’s laboratory is not a body of evidence. For scale, RIVM’s own laboratory work on eleven other products found nicotine at “64-91%” of the declared concentration, by a method RIVM itself flags as unvalidated.
Regulatory status in the United States
FDA’s authorised list says plainly: “There are 43 nicotine pouch products authorized by the FDA.” and “These are the only nicotine pouch products that may be lawfully sold in the United States.” The page’s content is current as of 21 August 2026. Peppermint 3 mg is on it. So is Peppermint 6 mg, and so is ZYN ULTRA Peppermint 9 mg.
Authorisation is not endorsement, and FDA says so in the same breath: “While these products are authorized to be sold in the United States, it does not mean these products are safe, nor are they ‘FDA approved.’ All tobacco products are harmful and potentially addictive.” It adds: “Those who do not use tobacco products shouldn’t start.”
Then there is the second, separate order. On 30 June 2026 FDA granted modified-risk orders covering twenty ZYN products, authorising this exact wording: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” The orders run “effective for 5 years from the issue date of this letter”. Appendix A enumerates the twenty covered products, and Peppermint 3 mg is the third of them, STN MR0000268.PD3.
Here is the hook worth carrying away: ZYN ULTRA Peppermint 9 mg is not in that appendix. Same flavour name, same shelf, and it may be sold — but it may not carry the reduced-risk claim, because the modified-risk order covers named products only, the ten flavours at 3 mg and 6 mg. Two cans with “Peppermint” on them have different legal standing depending on the number next to it.
Behind the claim, FDA’s review found that of “the 42 HPHCs analyzed in the new products, levels of 36 were too low to be quantified”, and that the products “do not contain measurable quantities of carcinogenic tobacco-specific nitrosamines, including NNN and NNK, or the carcinogenic polycyclic aromatic hydrocarbon B[a]P.” Carry FDA’s own footnote with that sentence, always: “Levels are not above the limit of quantitation (LOQ) of the analytical methods used in these PMTAs, though the applicant did not demonstrate that the new products are free from these chemicals.” Below the limit of detection is not the same as absent, and it is the regulator making the point.
None of this makes a nicotine pouch a quit aid, and FDA is emphatic that it must not be sold as one. Nicotine is addictive, and stopping entirely remains the lowest-risk course.
Where this flavour is not sellable
Peppermint is a characterizing flavour, and two US states ban those in terms that reach oral nicotine however it is derived.
Massachusetts names “menthol, mint, wintergreen” in its flavour definition and defines a “tobacco product” as one “containing or made or derived from tobacco or nicotine”. Its ban binds manufacturers and covers remote sales: “No person, retailer or manufacturer shall sell, distribute, cause to be sold or distributed, offer for sale any flavored tobacco product or tobacco product flavor enhancer in any retail establishment, online or through any other means to any consumer in the commonwealth”. The only exemption is smoking bars. The statute’s carve-out for FDA-approved cessation products does not rescue ZYN, because FDA says in both of its orders that it has not approved anything.
California names the same flavours — “menthol, mint, wintergreen, herb, or spice” — and exempts only hookah shisha in licensed lounges, premium cigars consumed on site, and “loose leaf tobacco or premium cigars”. The structural difference is worth knowing: California’s prohibition runs against retailers, with manufacturer conduct reaching the statute through a rebuttable presumption, where Massachusetts binds the manufacturer directly.
Who this suits
Peppermint 3 mg is the conservative choice in a ZYN mint: half the nicotine of the 6 mg in an identical 0.40 g pouch, so the per-gram concentration halves too rather than the pouch shrinking. That is not true as you climb the range — ZYN ULTRA’s 11 mg sits in a 0.8 g pouch, which works out per gram weaker than a standard 6 mg ZYN. The ladder is not a straight line, and the 3 mg rung is the one place it behaves exactly as you would expect. If you want the lowest nicotine load FDA has cleared, though, it is not a ZYN at all: on! is authorised at 2 mg in three flavours.
One thing the manufacturer will not help with: there is no beginner guidance anywhere on ZYN’s US site — no starting strength, no dose rule, nothing keyed to how much you currently smoke. An FDA-approved nicotine lozenge label carries an actual rule (“if you smoke your first cigarette more than 30 minutes after waking up, use 2 mg nicotine lozenge”). The pouch category has no equivalent.
Alternatives
Same strength, same maker, different flavour: ZYN Cool Mint 3mg and ZYN Wintergreen 3mg — and on FDA’s own bioequivalence finding, all three deliver nicotine the same way, so the choice is flavour alone. For the tier rather than the can, see the 3 mg tier and mg per pouch vs mg per gram; the range is mapped in the ZYN brand guide and the field in the master ranking.
What I could not establish
- No pH or free-base figure for this product. ZYN names its pH adjusters without a value; FDA’s review redacts the number as confidential commercial information.
- No independent measurement of any 3 mg ZYN’s actual nicotine content. The one published measurement of a ZYN is of a 6 mg mint, by a competitor’s laboratory.
- No pharmacokinetic study of this flavour. The bridge to the tested flavour is FDA’s bioequivalence statement, not a trial.
- No FDA enforcement action naming ZYN Peppermint. FDA’s April 2024 retailer warning letters concerned “unauthorized, flavored ZYN nicotine pouches, including Espressino, Black Cherry, Lemon Spritz, and Cucumber Lime” — none of which are in the authorised twenty, and all of which predate authorisation. I found no recall of any ZYN product, though I did not query FDA’s recall database directly, so read that as “none located” rather than “none exists”.
Sources
- FDA, Nicotine Pouch Products Authorized by the FDA — content current as of 21 August 2026.
- FDA, Marketing granted order to Swedish Match USA, STNs PM0000593.PD1–PM0000612.PD1, 16 January 2025, with Appendix A product specifications.
- FDA, Technical Project Lead review of PMTAs PM0000593.PD1–PM0000612.PD1 (68 pp).
- FDA, Modified risk granted orders, STNs MR0000268.PD1–MR0000268.PD20, 30 June 2026.
- Swedish Match North America, ZYN US FAQ — manufacturer specifications and ingredients.
- Bundesinstitut für Risikobewertung, Health risk assessment of nicotine pouches.
- RIVM, Nicotinezakjes, briefrapport 2020-0152.
- Mallock-Ohnesorg N. et al., Small pouches, but high nicotine doses, Frontiers in Pharmacology 15 (2024) — funded by BfR; authors declare no commercial relationships.
- Platt S.P. et al., Dissolution and physical characterization of oral nicotine pouch products, Scientific Reports, 6 January 2026 — funded by Altria Client Services; all authors Altria employees at the time of the study.
- Lunell E., Fagerström K., Hughes J., Pendrill R., “Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff”, Nicotine & Tobacco Research 2020;22(10):1757 — funded by Swedish Match AB. Cited here through RIVM’s and BfR’s restatements; the paper itself is paywalled.
- Massachusetts General Laws, c. 270 § 28.
- California Senate Bill 793, Chapter 34, Statutes of 2020, approved 28 August 2020.
- US National Library of Medicine, DailyMed label for nicotine polacrilex lozenge, 2 mg and 4 mg.
Last verified: 14 October 2026.